Literature DB >> 15327391

Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo.

Nimesh S A Patel1, Edward J Sharples, Salvatore Cuzzocrea, Prabal K Chatterjee, Domenico Britti, Muhammad M Yaqoob, Christoph Thiemermann.   

Abstract

BACKGROUND: Erythropoietin (EPO) is a potent stimulator of erythroid progenitor cells and is known to be up-regulated during states of hypoxia. Here we investigate the effects of renal ischemia/reperfusion (I/R) on the degree of renal dysfunction and injury with recombinant human EPO in mice when given as either a 3-day pretreatment, or upon reperfusion of the kidney.
METHODS: Mice were treated with EPO (1000 IU/kg/day subcutaneously) for 3 days, or treated with EPO (1000 IU/kg subcutaneously) upon reperfusion, and subsequently subjected to bilateral renal artery occlusion (30 minutes) and reperfusion (24 hours). At the end of experiments, the following indicators and markers of renal injury and dysfunction were measured: plasma urea, creatinine, and aspartate aminotransferase (AST), tissue myeloperoxidase (MPO) activity [for polymorphonuclear leukocyte (PMN) infiltration], and tissue malonaldehyde (MDA) levels (for tissue lipid peroxidation). Kidneys were used for histologic evaluation of renal injury.
RESULTS: EPO was able to significantly attenuate the renal dysfunction and injury associated with I/R, as well as the tissue injury. The increase in renal MPO activity and, hence, the degree of PMN infiltration were also significantly reduced in EPO-treated mice. In addition, lipid peroxidation as a result of renal I/R injury was also attenuated in EPO-treated mice.
CONCLUSION: The protection afforded by the pretreatment regime of EPO was greater than that of administering EPO as a single bolus upon reperfusion. We propose that different mechanisms underlie the protective effects seen with EPO when given as either a daily pretreatment or as a single bolus, which need to be further investigated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15327391     DOI: 10.1111/j.1523-1755.2004.00847.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  44 in total

1.  Benefit of Mineralocorticoid Receptor Antagonism in AKI: Role of Vascular Smooth Muscle Rac1.

Authors:  Jonatan Barrera-Chimal; Gwennan André-Grégoire; Aurelie Nguyen Dinh Cat; Sebastian M Lechner; Jérôme Cau; Sonia Prince; Peter Kolkhof; Gervaise Loirand; Vincent Sauzeau; Thierry Hauet; Frédéric Jaisser
Journal:  J Am Soc Nephrol       Date:  2017-01-13       Impact factor: 10.121

2.  Effect of high-dose erythropoietin on graft function after kidney transplantation: a randomized, double-blind clinical trial.

Authors:  Kalathil K Sureshkumar; Sabiha M Hussain; Tina Y Ko; Ngoc L Thai; Richard J Marcus
Journal:  Clin J Am Soc Nephrol       Date:  2012-06-28       Impact factor: 8.237

3.  In-vivo monitoring of erythropoietin treatment after myocardial infarction in mice with [⁶⁸Ga]Annexin A5 and [¹⁸F]FDG PET.

Authors:  Andrei Todica; Mathias J Zacherl; Hao Wang; Guido Böning; Nathalie L Jansen; Carmen Wängler; Peter Bartenstein; Michael C Kreissl; Marcus Hacker; Stefan Brunner; Sebastian Lehner
Journal:  J Nucl Cardiol       Date:  2014-09-05       Impact factor: 5.952

4.  Circulating levels of erythropoietin and its relation to arterial stiffness in patients with hypertension.

Authors:  Omer Gedikli; Abdulkadir Kiris; Caner Karahan
Journal:  Int J Clin Exp Med       Date:  2013-09-01

5.  The cellular origin and proliferative status of regenerating renal parenchyma after mercuric chloride damage and erythropoietin treatment.

Authors:  T-H Yen; M R Alison; H T Cook; R Jeffery; W R Otto; N A Wright; R Poulsom
Journal:  Cell Prolif       Date:  2007-04       Impact factor: 6.831

6.  JAK2/Y343/STAT5 signaling axis is required for erythropoietin-mediated protection against ischemic injury in primary renal tubular epithelial cells.

Authors:  A C Breggia; D M Wojchowski; J Himmelfarb
Journal:  Am J Physiol Renal Physiol       Date:  2008-09-24

Review 7.  Erythropoietin.

Authors:  H Franklin Bunn
Journal:  Cold Spring Harb Perspect Med       Date:  2013-03-01       Impact factor: 6.915

8.  Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin.

Authors:  Michael Brines; Nimesh S A Patel; Pia Villa; Courtenay Brines; Tiziana Mennini; Massimiliano De Paola; Zubeyde Erbayraktar; Serhat Erbayraktar; Bruno Sepodes; Christoph Thiemermann; Pietro Ghezzi; Michael Yamin; Carla C Hand; Qiao-wen Xie; Thomas Coleman; Anthony Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-01       Impact factor: 11.205

9.  Donor treatment with a PHD-inhibitor activating HIFs prevents graft injury and prolongs survival in an allogenic kidney transplant model.

Authors:  W M Bernhardt; U Gottmann; F Doyon; B Buchholz; V Campean; J Schödel; A Reisenbuechler; S Klaus; M Arend; L Flippin; C Willam; M S Wiesener; B Yard; C Warnecke; K-U Eckardt
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-23       Impact factor: 11.205

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.